Sofgen Pharma S.A. - PROCF
Detailed investor-level table based on 13F positions.
Methodology:
Market value and % of portfolio use SEC reported VALUE ($000).
For PUT/CALL positions this reflects reported underlying exposure, not premium cash paid/received.
Details.
Rows: 0
| Investor | History | Status | Shares held | Market value ($000) | % of portfolio | Previous % | Rank | Change in shares | % change in shares | Source | Date reported |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | History | Added to | 28,938 | 89 | 0.0% | 0.0% | 1 | +3,552 | 13.99% | Q1 2024 | May 13, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | History | New | 25,300 | 73 | 0.0% | — | 2 | +25,300 | New | Q1 2024 | May 13, 2024 |
| CITADEL ADVISORS LLC | History | New | 12,500 | 38 | 0.0% | — | 4 | +12,500 | New | Q1 2024 | May 15, 2024 |
| STATE STREET CORP | History | Added to | 12,363 | 38 | 0.0% | 0.0% | 3 | +125 | 1.02% | Q1 2024 | May 15, 2024 |
| ROYAL BANK OF CANADA | History | Added to | 362 | 1 | 0.0% | 0.0% | 5 | +157 | 76.59% | Q1 2024 | Nov 05, 2024 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | History | Closed out | 0 | 0 | — | 0.0% | — | -36,385 | -100.0% | Q1 2024 | May 07, 2024 |
| UBS Group AG | History | Reduced | 42 | 0 | — | 0.0% | — | -30,986 | -99.86% | Q1 2024 | May 13, 2024 |
| JPMORGAN CHASE & CO | History | Closed out | 0 | 0 | — | 0.0% | — | -745 | -100.0% | Q1 2024 | May 10, 2024 |
| MORGAN STANLEY | History | No change | 100 | 0 | — | — | — | 0 | 0.0% | Q1 2024 | May 15, 2024 |